Study Description:
Psoriasis is a Th17 linked inflammatory disease and we find that the vitamin B3 analogue nicotinamide riboside (NR) blunts Th1 and Th17 activation in ex-vivo na(SqrRoot) ve and differentiated T cells from control and psoriasis subjects. These findings supported the proposal of the following hypothesis. Supplementation with NR will blunt systemic immune activation in mild/moderate psoriasis.
Objectives- Evaluate the effect of NR on Th17 biology
- Explore the effect of NR on neutrophils, specifically lowdensity granulocytes
- Evaluate whether NR modulates keratinocyte activation in skin lesions in psoriatic subjects
- Evaluate the effect of NR on HDL regulated reverse cholesterol transport and lipid composition
The primary outcome will be the change in the TH17 cell cytokine IL-17 secretion in response to T-cell differentiation comparing the baseline versus NR or placebo. The comparisons will be performed using paired two-tailed Student t-tests. Significance will be tested at
the 0.05 alpha level in this pilot study.
Secondary outcomes are:
- Evaluate the effect of NR on the T cell transcriptome
- Explore the effect of NR on low-density granulocytes and neutrophils
- Evaluate whether NR modulates keratinocyte activation in skin lesions in psoriatic subjects
- Evaluate the effect of NR on HDL regulated reverse cholesterol transport and lipid composition by NMR spectroscopy
Study Population:
Up to 40 male and female subjects of all races between the ages of 18-70 years with mild-moderate psoriasis who live locally will be screened.
PhaseN/A
Description of Sites/Facilities:
Enrollment and study visits will take place at the NIH Clinical Center.
Enrolling Participants:
Psoriatic Subjects
Description of Study Intervention:
Nicotinamide Riboside Chloride 500mg or placebo twice daily by mouth for 28 days.
Study Duration:
3 years
Participant Duration:
5-7 weeks
